Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,shortLongTermDebt,shortTermInvestments,longTermDebt,treasuryStock,otherStockholderEquity,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,investments,netBorrowings,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,EOLS,32620000.0,54120300,499000,,-15601000,,-15601000,26472000,14796000,-13921000,-13921000,,-300000,,,,0,26098000,40019000,11302000,-1680000,,-15601000,-15601000,52310000.0,491409000.0,133725000.0,106138000.0,38517000.0,239863000.0,1000.0,9215000.0,-385272000.0,43725000.0,21208000.0,240000.0,131737000.0,87286000.0,4215000.0,161890000.0,11864000.0,3337000.0,8059000.0,,,,,,259000.0,-386000.0,93836000.0,32183000.0,95033000.0,109566000.0,16116000.0,1916000.0,-3129000.0,-3751000.0,-1197000.0,3945000.0,,,,74604000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.0377415,10.45 - 10.8,10.6,10.53,10.55,10,22,finmb_229087176,NasdaqGM,USD,508176,469900,7.64,2.6807017,2.85 - 17.38,-6.8899994,-0.39643267,2.85,17.38,1616616000,1635364800,1635796800,-3.958,-0.41,-0.85,-12.341176,-14400000,0.532,11.050555,-0.56055546,-0.05072645,11.335326,-0.8453264,2,"Evolus, Inc. Common Stock","Evolus, Inc.",10.49,1630509508,-0.11000061,10.65,10.8,10.45,51195,REGULAR,NGM,us_market,-0.074574515,567721920,-25.585365,19.718044,15,America/New_York,EDT,False,False,0,2.3,,,17.38,2.85,11.05,11.34,508.18k,469.9k,54.12M,,33.6M,37.76%,31.48%,3.2M,7.75,8.57%,5.87%,3.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-171.53%,-75.82%,-16.71%,-175.44%,76.58M,1.97,234.30%,38.24M,-50.66M,-131.35M,-3.96,,131.74M,2.41,23.6M,22.24,1.86,0.53,-8.2M,19.32M,Value,92660,Healthcare,130,10,8,"Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",Newport Beach,949 284 4555,CA,8,1609372800,1625097600,9,United States,http://www.evolus.com,86400,10,520 Newport Center Drive,Drug Manufacturers—Specialty & Generic,Suite 1200
t-1,EOLS,-51487000.0,54120300,841000,,6401000,,6401000,20677000,7333000,-16218000,-16218000,,-645000,,,,0,12241000,28459000,4908000,22619000,,6401000,6401000,53568000.0,392959000.0,133909000.0,23289000.0,44359000.0,157198000.0,1000.0,39491000.0,-369671000.0,43325000.0,21208000.0,240000.0,22171000.0,87648000.0,4465000.0,77717000.0,7816000.0,2775000.0,13253000.0,,,,,,-1808000.0,4785000.0,-76841000.0,-24525000.0,11000.0,-80391000.0,-8335000.0,2199000.0,3149000.0,1254000.0,-529000.0,4709000.0,5000000.0,-76323000.0,,-9931000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.0377415,10.45 - 10.8,10.6,10.53,10.55,10,22,finmb_229087176,NasdaqGM,USD,508176,469900,7.64,2.6807017,2.85 - 17.38,-6.8899994,-0.39643267,2.85,17.38,1616616000,1635364800,1635796800,-3.958,-0.41,-0.85,-12.341176,-14400000,0.532,11.050555,-0.56055546,-0.05072645,11.335326,-0.8453264,2,"Evolus, Inc. Common Stock","Evolus, Inc.",10.49,1630509508,-0.11000061,10.65,10.8,10.45,51195,REGULAR,NGM,us_market,-0.074574515,567721920,-25.585365,19.718044,15,America/New_York,EDT,False,False,0,2.3,,,17.38,2.85,11.05,11.34,508.18k,469.9k,54.12M,,33.6M,37.76%,31.48%,3.2M,7.75,8.57%,5.87%,3.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-171.53%,-75.82%,-16.71%,-175.44%,76.58M,1.97,234.30%,38.24M,-50.66M,-131.35M,-3.96,,131.74M,2.41,23.6M,22.24,1.86,0.53,-8.2M,19.32M,Value,92660,Healthcare,130,10,8,"Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",Newport Beach,949 284 4555,CA,8,1609372800,1625097600,9,United States,http://www.evolus.com,86400,10,520 Newport Center Drive,Drug Manufacturers—Specialty & Generic,Suite 1200
t-2,EOLS,-149463000.0,54120300,719000,,-110844000,,-110694000,27394000,13299000,-16690000,-16690000,,-2823000,,,,-150000,20577000,37267000,7278000,-94154000,,-110694000,-110694000,55297000.0,303113000.0,282026000.0,-72958000.0,89016000.0,209068000.0,1000.0,1350000.0,-376072000.0,58125000.0,21208000.0,240000.0,102562000.0,180248000.0,4711000.0,127612000.0,9680000.0,3354000.0,9615000.0,74384000.0,5000000.0,40506000.0,,,5165000.0,19701000.0,-76841000.0,36692000.0,11000.0,17435000.0,-2266000.0,2040000.0,3006000.0,2092000.0,-529000.0,58735000.0,20000000.0,-76323000.0,-17000.0,-52636000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.0377415,10.45 - 10.8,10.6,10.53,10.55,10,22,finmb_229087176,NasdaqGM,USD,508176,469900,7.64,2.6807017,2.85 - 17.38,-6.8899994,-0.39643267,2.85,17.38,1616616000,1635364800,1635796800,-3.958,-0.41,-0.85,-12.341176,-14400000,0.532,11.050555,-0.56055546,-0.05072645,11.335326,-0.8453264,2,"Evolus, Inc. Common Stock","Evolus, Inc.",10.49,1630509508,-0.11000061,10.65,10.8,10.45,51195,REGULAR,NGM,us_market,-0.074574515,567721920,-25.585365,19.718044,15,America/New_York,EDT,False,False,0,2.3,,,17.38,2.85,11.05,11.34,508.18k,469.9k,54.12M,,33.6M,37.76%,31.48%,3.2M,7.75,8.57%,5.87%,3.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-171.53%,-75.82%,-16.71%,-175.44%,76.58M,1.97,234.30%,38.24M,-50.66M,-131.35M,-3.96,,131.74M,2.41,23.6M,22.24,1.86,0.53,-8.2M,19.32M,Value,92660,Healthcare,130,10,8,"Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",Newport Beach,949 284 4555,CA,8,1609372800,1625097600,9,United States,http://www.evolus.com,86400,10,520 Newport Center Drive,Drug Manufacturers—Specialty & Generic,Suite 1200
t-3,EOLS,-42904000.0,54120300,350000,,-11486000,,-11459000,21944000,12807000,-11231000,-11231000,,-2758000,,,,-27000,17661000,28892000,4854000,-255000,,-11459000,-11459000,56791000.0,300469000.0,180684000.0,35095000.0,4501000.0,215779000.0,1000.0,,-265378000.0,50458000.0,21208000.0,440000.0,85127000.0,12709000.0,4940000.0,132400000.0,11399000.0,4871000.0,2957000.0,,24996000.0,114177000.0,3000.0,3000.0,3730000.0,29301000.0,39767000.0,-7750000.0,11000.0,55355000.0,-13713000.0,1904000.0,1266000.0,-2582000.0,-233000.0,475000.0,30000000.0,40000000.0,-121000.0,119691000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.0377415,10.45 - 10.8,10.6,10.53,10.55,10,22,finmb_229087176,NasdaqGM,USD,508176,469900,7.64,2.6807017,2.85 - 17.38,-6.8899994,-0.39643267,2.85,17.38,1616616000,1635364800,1635796800,-3.958,-0.41,-0.85,-12.341176,-14400000,0.532,11.050555,-0.56055546,-0.05072645,11.335326,-0.8453264,2,"Evolus, Inc. Common Stock","Evolus, Inc.",10.49,1630509508,-0.11000061,10.65,10.8,10.45,51195,REGULAR,NGM,us_market,-0.074574515,567721920,-25.585365,19.718044,15,America/New_York,EDT,False,False,0,2.3,,,17.38,2.85,11.05,11.34,508.18k,469.9k,54.12M,,33.6M,37.76%,31.48%,3.2M,7.75,8.57%,5.87%,3.51M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-171.53%,-75.82%,-16.71%,-175.44%,76.58M,1.97,234.30%,38.24M,-50.66M,-131.35M,-3.96,,131.74M,2.41,23.6M,22.24,1.86,0.53,-8.2M,19.32M,Value,92660,Healthcare,130,10,8,"Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.",Newport Beach,949 284 4555,CA,8,1609372800,1625097600,9,United States,http://www.evolus.com,86400,10,520 Newport Center Drive,Drug Manufacturers—Specialty & Generic,Suite 1200
